Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00795509 |
Recruitment Status :
Completed
First Posted : November 21, 2008
Results First Posted : July 9, 2012
Last Update Posted : July 9, 2012
|
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | November 19, 2008 | |||
First Posted Date | November 21, 2008 | |||
Results First Submitted Date | March 7, 2012 | |||
Results First Posted Date | July 9, 2012 | |||
Last Update Posted Date | July 9, 2012 | |||
Study Start Date | August 2007 | |||
Actual Primary Completion Date | March 2011 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures |
|
|||
Original Primary Outcome Measures |
|
|||
Change History | ||||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan). | |||
Official Title | Special Investigation For Long Term Use Of Detrusitol (Regulatory Post Marketing Commitment Plan). | |||
Brief Summary | The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug. | |||
Detailed Description | All the patients whom an investigator prescribes the first Detrusitol® Capsule should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random. | |||
Study Type | Observational | |||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Probability Sample | |||
Study Population | The patients whom an investigator involving A6121187 prescribes the Tolterodine tartrate (Detrusitol® Capsule). | |||
Condition | Urinary Bladder, Overactive | |||
Intervention | Drug: Tolterodine tartrate
Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
Other Name: Detrusitol® Capsule.
|
|||
Study Groups/Cohorts | Tolterodine tartrate.
Patients taking Tolterodine tartrate.
Intervention: Drug: Tolterodine tartrate
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment |
374 | |||
Original Estimated Enrollment |
100 | |||
Actual Study Completion Date | March 2011 | |||
Actual Primary Completion Date | March 2011 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender |
|
|||
Ages | Child, Adult, Older Adult | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00795509 | |||
Other Study ID Numbers | A6121187 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor | Pfizer | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | Pfizer | |||
Verification Date | June 2012 |